openPR Logo
Press release

Adrenocortical Carcinoma Pipeline Outlook Report 2025: Insights Into Therapies, Research, and Market Potential

09-05-2025 09:20 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Adrenocortical Carcinoma Pipeline Outlook Report 2025:

DelveInsight's, "Adrenocortical Carcinoma Pipeline Insight 2025" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Adrenocortical Carcinoma pipeline landscape. It covers the Adrenocortical Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Adrenocortical Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Adrenocortical Carcinoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Adrenocortical Carcinoma Pipeline Outlook [https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Adrenocortical Carcinoma Pipeline Report

* In August 2025, Fusion Pharmaceuticals Inc . conducted a study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of [225Ac]-FPI-1434 (radioimmuno-therapeutic agent) in patients with solid tumours that demonstrate uptake of [111In]-FPI-1547 (radioimmuno-imaging agent), and to establish the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of repeat doses of [225Ac]-FPI-1434 Injection in patients with solid tumours that demonstrate uptake of [111In]-FPI-1547 (radioimmuno-imaging agent).
* DelveInsight's Adrenocortical Carcinoma Pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Adrenocortical Carcinoma treatment.
* The leading Adrenocortical Carcinoma Companies such as Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech and others.
* Promising Adrenocortical Carcinoma Pipeline Therapies such as Pembrolizumab, Sunitinib, OSI-906, Iressa (ZD1839), Osilodrostat, TKM-080301, Axitinib, Dostarlimab, Chemotherapy, Ipilimumab, Nivolumab and others.

Stay ahead with the most recent pipeline outlook for Adrenocortical Carcinoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Adrenocortical Carcinoma Treatment Drugs [https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Adrenocortical Carcinoma Emerging Drugs Profile

* CY-101: Cytovation

CyPep-1 is a proprietary first-in-class targeted tumor membrane immunotherapy engineered to selectively target cancer cells. Administered by intratumoral injection, CyPep-1 eliminates cancer cells by forming pores in the plasma membrane, releasing cancer specific antigens to the immune system, promoting an inflammatory microenvironment, and inducing a systemic, tumor-specific immune response. A synthetic peptide, CyPep-1 has been designed for easy and scalable manufacturing and is highly stable - an uncommon feature in these molecules. Currently, the drug is in Phase II stage of its clinical trial as per the Company Pipeline for the treatment of Adrenocortical Carcinoma.

The Adrenocortical Carcinoma Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Adrenocortical Carcinoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Adrenocortical Carcinoma Treatment.
* Adrenocortical Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Adrenocortical Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Adrenocortical Carcinoma market

Explore groundbreaking therapies and clinical trials in the Adrenocortical Carcinoma Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Adrenocortical Carcinoma Drugs [https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Adrenocortical Carcinoma Companies

Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech and others.

Adrenocortical Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Unveil the future of Adrenocortical Carcinoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Adrenocortical Carcinoma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Adrenocortical Carcinoma Market Report

* Coverage- Global
* Adrenocortical Carcinoma Companies- Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech and others.
* Adrenocortical Carcinoma Pipeline Therapies such as Pembrolizumab, Sunitinib, OSI-906, Iressa (ZD1839), Osilodrostat, TKM-080301, Axitinib, Dostarlimab, Chemotherapy, Ipilimumab, Nivolumab and others.
* Adrenocortical Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Adrenocortical Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Adrenocortical Carcinoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Adrenocortical Carcinoma Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Adrenocortical Carcinoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Adrenocortical Carcinoma- DelveInsight's Analytical Perspective
* Mid Stage Products (Phase II)
* Ipilimumab: Bristol-Myers Squibb
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Relacorilant: Corcept Therapeutics
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Adrenocortical Carcinoma Key Companies
* Adrenocortical Carcinoma Key Products
* Adrenocortical Carcinoma- Unmet Needs
* Adrenocortical Carcinoma- Market Drivers and Barriers
* Adrenocortical Carcinoma- Future Perspectives and Conclusion
* Adrenocortical Carcinoma Analyst Views
* Adrenocortical Carcinoma Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=adrenocortical-carcinoma-pipeline-outlook-report-2025-insights-into-therapies-research-and-market-potential]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/adrenocortical-carcinoma-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Adrenocortical Carcinoma Pipeline Outlook Report 2025: Insights Into Therapies, Research, and Market Potential here

News-ID: 4172245 • Views:

More Releases from ABNewswire

Minimally Invasive Neurosurgery of Texas Publishes Expert Insights on Tailbone Pain Treatment Spine Clinic Plano TX and Long-Term Pelvic Floor Function
Minimally Invasive Neurosurgery of Texas Publishes Expert Insights on Tailbone P …
Plano, TX - October 30, 2025 - Minimally Invasive Neurosurgery of Texas shares expert insights on how specialized care at a tailbone pain treatment spine clinic Plano TX can relieve chronic discomfort while supporting long-term pelvic floor health and mobility. Visit us here [https://minimallyinvasiveneurosurgerytexas.com/choosing-the-right-back-doctor-plano-tx-expert-spine-solutions/] to learn more. Minimally Invasive Neurosurgery of Texas, a leader in advanced spinal care, is sharing valuable insights into the connection between effective tailbone pain relief and
Big Mountains Guy Productions Elevates Sports Storytelling with High-Impact Visuals
Big Mountains Guy Productions Elevates Sports Storytelling with High-Impact Visu …
From high-altitude mountain biking to the pulse of team competition, Big Mountains Guy isn't just documenting the action - they're immersing audiences in it. The studio's work combines state-of-the-art video technology with an unfiltered approach to storytelling, showing the grit, grace, and human drive behind every performance. SEATTLE, WA - October 30, 2025 - In a world where attention spans are short but passion runs deep, Big Mountains Guy Photography &
What Happens When Streets Must Change Overnight? Adaptive Barriers Step In
What Happens When Streets Must Change Overnight? Adaptive Barriers Step In
Cities rarely sleep, yet their streets must turn before sunrise. Emergencies, festivals, and repairs demand instant redesigns that balance access, safety, and flow. Overnight conversions test how prepared a city truly is, turning curbs and lanes into flexible assets rather than fixed obstacles. Adaptive tools now make those transformations predictable. Removable barriers, portable lights, and premarked anchor points let teams reshape corridors without chaos. Each operation becomes a real-time rehearsal in
Leadership Strategist Jessper Maquindang to Lead SCORE Los Angeles Workshop on Building High-Performing Teams
Leadership Strategist Jessper Maquindang to Lead SCORE Los Angeles Workshop on B …
Los Angeles, California - Small business owners seeking to strengthen teamwork, boost morale, and elevate performance are invited to join a virtual workshop led by leadership strategist Jessper Maquindang, SPHR, founder of FamiLEAD Management Consulting [https://www.famileadconsulting.com/]. Hosted by SCORE Los Angeles, the live session, titled "Stronger Teams, Stronger Business: Strategies to Boost Collaboration, Engagement, and Performance," equips entrepreneurs with practical frameworks for building cohesive, high-performing teams that drive business success. Image:

All 5 Releases


More Releases for Adrenocortical

Adrenocortical Hormones API Market Size to Expand Lucratively by 2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Adrenocortical Hormones API Market - (By Type (Dexamethasone Series, Betamethasone Series, Hydrocortisone Series & Others), By Application (Injectable Drugs, Oral Drugs, For External Use Drugs, Inhalation Drugs)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by InsightAce Analytic, the Global Adrenocortical Hormones API Market is valued at US$ 2.24 Billion
Adrenocortical Carcinoma Drugs Market Overview: Growth, Share, Value, Size, and …
The global Adrenocortical Carcinoma Drugs market is projected to reach approximately USD 0.85 billion by 2033, growing at a compound annual growth rate (CAGR) of around 7.2% from 2025 to 2033. Adrenocortical Carcinoma Drugs Market Overview The global Adrenocortical Carcinoma (ACC) drugs market is experiencing growth, driven by the increasing incidence of this rare endocrine malignancy and advancements in therapeutic approaches. ACC is characterized by aggressive tumor behavior and limited treatment options,
Adrenocortical Hormones API Market Survey Detailed Analysis and Forecast 2024-20 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Adrenocortical Hormones API Market - (By Type (Dexamethasone Series, Betamethasone Series, Hydrocortisone Series & Others), By Application (Injectable Drugs, Oral Drugs, For External Use Drugs, Inhalation Drugs)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by InsightAce Analytic, the Global Adrenocortical Hormones API Market is valued at US$ 2.24 Billion
Adrenocortical Carcinoma Treatment: Challenges, Advances, and Market Dynamics
Adrenocortical carcinoma (ACC) is a rare and aggressive form of cancer originating in the adrenal cortex, the outer layer of the adrenal glands. These glands, located above the kidneys, are responsible for producing hormones that regulate a variety of bodily functions, such as metabolism, blood pressure, and immune response. ACC is often diagnosed at an advanced stage due to its asymptomatic early course, and treatment options are limited. In this
Adrenocortical Hormones API Market Research Explores Revenue Share Study Analysi …
Adrenocortical Hormones API Market is valued at US$ 2.24 Billion in 2023, and it is expected to reach US$ 3.55 Billion by 2031, with a CAGR of 6.04 % during the forecast period of 2024-2031. InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Adrenocortical Hormones API Market - (By Type (Dexamethasone Series, Betamethasone Series, Hydrocortisone Series & Others), By Application (Injectable Drugs, Oral Drugs,
Adrenocortical Hormones API Market to Witness Robust Expansion by 2025
LP INFORMATION recently released a research report on the Adrenocortical Hormones API market analysis and elaborate the industry coverage, current market competitive status, and market outlook and forecast by 2025. Moreover, it categorizes the global Adrenocortical Hormones APImarket by key players, product type, applications and regions,etc. The main objective of this market research is to help the readers understand the structure of Adrenocortical Hormones APImarket, market definition, overview, industry opportunities